Abstract
Since February 2022, patients at Leeds Teaching Hospitals with PF-ILD have been offered treatment with Nintedanib. We aimed to identify characteristics that may predict Nintedanib tolerance in this cohort.We performed...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
